Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07207512
Recruiting Not applicable

Emotion-Focused Therapy in the Treatment of Prolonged Grief Disorder

NCT07207512 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-04-06
Last updated
2026-09-02

Condition(s) studied

Prolonged Grief Disorder (PGD)

Investigational drug(s) / intervention(s)

Emotion-Focused Therapy for GriefSelf-help intervention based on EFT

Emotion-Focused Therapy for Grief: The EFT intervention will follow the model described in EFT for grief. Its main goal is to transform core emotional pain (e.g., chronic shame) by activating change-inducing emotions (e.g., assertive anger), a process described as "changing emotion with emotion." This work takes place within a safe and supportive therapeutic relationship, characterized by the therapist's empathic, accepting, and compassionate stance. Therapists remain attuned to emotional markers (e.g., self-criticism, unfinished business) that signal opportunities for targeted work on specific affective problems, which are usually addressed through experiential tasks such as the Empty-Chair for Unfinished Business. Although EFT is transdiagnostic, grief work has certain distinctive features, such as the central role of experiencing grief-related sadness and fostering a sense of connection with the deceased.

Self-help intervention based on EFT: The self-help intervention consists of 10 written exercises designed to address different aspects of grief. These include psychoeducation, emotional regulation, focusing on bodily awareness, softening self-criticism, reducing avoidance, managing anxiety and fear, clarifying confusing emotional reactions, processing trauma, imaginal dialogues with the deceased, and cultivating compassion.

Study summary

The goal of this clinical trial is to learn if Emotion-Focused Therapy (EFT) works to reduce symptoms of Prolonged Grief Disorder (PGD) in adults. PGD happens when the pain of losing a loved one lasts a long time and causes serious problems in daily life.

* The main questions this study aims to answer are:

1. Does EFT lower grief symptoms in adults with PGD?
2. Does EFT also help with related problems, such as anxiety, depression, trauma, and overall distress?
* Who can take part:

Adults (18 years or older) who lost a loved one at least 6 months ago and meet the criteria for PGD.

\- What will happen in the study:

Participants will be randomly assigned to one of two groups:

1. EFT group: 8 to 10 weekly, face-to-face therapy sessions with a trained therapist.
2. Self-help group: 10 weekly self-help exercises based on EFT, completed on their own.

* All participants will complete questionnaires on grief, mood, and well-being before starting, during the study, at the end of treatment (12 weeks), and again at 5 months and 12 months after starting.
* In the EFT group, the therapeutic relationship will also be measured during sessions 3 and 8.
* Why this study is important:

Most current treatments for grief are based on cognitive-behavioral therapy, but not everyone benefits from them. EFT is a promising therapy that focuses on emotions and has shown positive results for other mental health problems. This trial will test if EFT can be an effective treatment for people struggling with prolonged grief.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years). * Undergoing a grief process (including perinatal grief). * Meeting ICD-11 diagnostic criteria for Prolonged Grief Disorder, assessed with the Traumatic Grief Inventory - Clinician Administered (TGI-CA); death occurred six months or more prior to assessment; PG-13-R score ≥30. * Provision of informed consent. * Stable psychopharmacological medication for at least six weeks prior to therapy onset, with physician approval to maintain stability during the intervention. Exclusion Criteria: * Concurrent psychological treatment * Bereavement occurring less than six months prior to the loss * Substance abuse * Eating disorder * Psychosis; * Organic brain syndrome * Suicide risk * Risk of harm to others.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Unidad Clínica de Psicología de la Universidad Pontificia Comillas (UNINPSI) Madrid Madrid Recruiting

More Universidad Pontificia Comillas trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07207512 on ClinicalTrials.gov ↗ ← All trials in Spain